$HAE News

Earnings Preview: Haemonetics (HAE) Q1 Earnings Expected to Decline

Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $90

Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026

3 Reasons HAE is Risky and 1 Stock to Buy Instead

BTIG Reiterates Buy on Haemonetics, Maintains $84 Price Target

BTIG Reiterates Buy on Haemonetics, Maintains $84 Price Target

Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $85

A Look At Haemonetics (HAE) Valuation After Its New Apheresis And MedSurg Segment Realignment

Haemonetics Corporation (HAE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Haemonetics Updates Financial Reporting Segments

Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference

Citigroup Maintains Neutral on Haemonetics, Raises Price Target to $70

Why Haemonetics (HAE) Is Up 14.3% After Earnings Beat And BofA Upgrade And What's Next

Haemonetics (HAE) Stock Is Up, What You Need To Know

Medical Devices & Supplies - Specialty Stocks Q1 Highlights: Haemonetics (NYSE:HAE)

B of A Securities Upgrades Haemonetics (HAE)

Investing in Haemonetics (HAE)? Don't Miss Assessing Its International Revenue Trends

B of A Securities Upgrades Haemonetics to Buy, Raises Price Target to $80

Does Haemonetics (HAE) Have Enduring Growth Potential?

3 Russell 2000 Stocks That Concern Us